



Buy EUR 290.00	(Hold)	Value Indicators: DCF:	EUR 290.22	Warburg Risk Score: Balance Sheet Score: Market Liquidity Score:	3.3 4.0 2.5	Description: Technology-based financial provider	services
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2024e
		Market cap:	1,486.44	Freefloat	61.70 %	Beta:	1.2
Price	EUR 222.40	No. of shares (m):	6.68	Revenia (Ronald Slabke)	34.60 %	Price / Book:	4.3 x
Upside	30.4 %	EV:	1,577.15	Treasury shares	3.70 %	Equity Ratio:	56 %
		Freefloat MC:	917.14			Net Fin. Debt / EBITDA:	2.1 x
		Ø Trad. Vol. (30d):	1.93 m			Net Debt / EBITDA:	2.1 x

German mortgage market continued to recover in Q3

Stated Fig	ures Q3	/2024:						
in EUR m	Q3/24	Q3/23	уоу	Q3/24e	Δ WRe	9M/24	9M/23	уоу
RE&M								
Revenue	80.3	56.8	41%	81.1	-1%	230.5	170.5	35%
EBIT	5.8	1.7	236%	7.0	-17%	20.5	5.7	259%
margin	7.2%	3.1%		8.7%		8.9%	3.4%	
Financing Pla	atform							
Revenue	18.1	16.3	11%	17.3	4%	54.4	51.3	6%
EBIT	1.1	-0.4	-358%	0.8	46%	3.2	2.2	45%
margin	6.2%	-2.7%		4.4%		5.9%	4.3%	
Insurance Pla	atform							
Revenue	15.9	16.3	-2%	17.6	-10%	48.4	47.3	2%
EBIT	0.4	0.4	-8%	0.5	-20%	0.9	0.1	1479%
margin	2.5%	2.7%		2.8%		1.9%	0.1%	
Consolidatio	n effects							
Revenue	-0.3	-0.4	-14%	-1.0		-1.4	-0.9	45%
EBIT	-3.7	-3.8	-3%	-4.6		-13.1	-11.8	11%
Group								
Revenue	113.9	89.0	28%	114.9	-1%	332.0	268.1	24%
EBIT	3.7	-2.1	-277%	3.7	0%	11.6	-3.8	-405%
margin	3.2%	-2.3%		3.2%		3.5%	-1.4%	

Comment on Figures:

- Real Estate & Mortgage benefited from the general recovery of the German mortgage market, which boosted revenues at Europace. However, growth was still held back by the shortening of fixed interest periods and low contributions from a large private bank due to internal IT issues. Furthermore, revenues from valuation services declined by -9% after 9M, burdening the EBIT margin of the segment with a negative EBIT of EUR -5.6m.
- The Financing Platform segment grew notably, although the market environment remained challenging. The transaction volume in private loans grew by +15% to EUR 4.8bn after 9M, despite banks becoming more restrictive against the backdrop of a deteriorating macroeconomic environment. While the performance of private loans was encouraging, financing volumes from institutional clients and corporate finance volumes suffered from a challenging political environment lacking stimulus.
- The Insurance Platform segment showed a rather flattish trend, but continued to operate on a profitable basis.


Hypoport's final 9M results were in line with the preliminary figures and our expectations. The company reiterated its 2024 guidance for EBIT between EUR 10m and EUR 20m, which has already been achieved after 9M.

- The overall development was characterised by the ongoing recovery of the German mortgage market. Although the political environment has yet to show any signs of support, the number of transactions for existing houses continued to rise on the back of rising rents, slightly growing house prices and lower interest rates.
- For 2025, CEO Slabke expects the recovery to continue, which should then translate into significant double-digit growth rates for Hypoport, especially on the EBIT line, which should further benefit from lower negative contributions from certain operations such as the valuation business.

Assessment: With the third consecutive quarter of significant volume growth, the German mortgage market should finally be considered to be in a recovery mode. This should be fuelled further by weak construction activity, which limits supply to the market and results in increasing house prices. While little support from an improving political framework is expected for the institutional housing and corporate finance business over the next two quarters, a new government could bring a change for the better. However, after the recent share-price weakness, our unchanged PT of EUR 290 offers plenty of upside potential, which is why we are upgrading our rating to Buy.

350 -	FY End: 31.12. in EUR m	CAGR (23-26e)	2020	2021	2022	2023	2024e	2025e	2026e
300 - / Mar	Sales	17.2 %	387.73	446.35	455.45	359.89	456.13	523.97	580.04
275 -	Change Sales yoy		15.0 %	15.1 %	2.0 %	-21.0 %	26.7 %	14.9 %	10.7 %
250 -	Gross profit margin		59.7 %	61.2 %	62.6 %	64.3 %	57.6 %	59.6 %	61.1 %
225 - M	EBITDA	23.5 %	63.85	77.10	57.71	51.18	43.08	71.38	96.51
200 - M du A	" Margin		16.5 %	17.3 %	12.7 %	14.2 %	9.4 %	13.6 %	16.6 %
175 - July V	EBIT	66.3 %	36.24	47.68	24.68	13.30	15.82	39.24	61.21
150 - W	Margin		9.3 %	10.7 %	5.4 %	3.7 %	3.5 %	7.5 %	10.6 %
125 from many many many	~ Net income	31.6 %	27.27	30.16	18.69	20.14	10.60	28.82	45.91
01/24 03/24 05/24 07/24 09/24 1	1/24 EPS	31.7 %	4.36	4.83	2.96	3.01	1.59	4.31	6.87
	EPS adj.	31.7 %	4.36	4.83	2.96	3.01	1.59	4.31	6.87
— Hypoport SE — MDAX (normalised)	DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Rel. Performance vs MDAX:	Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	FCFPS		1.59	4.35	0.41	3.53	-0.49	3.49	6.62
1 month: -22.2	FOF / Warket Cap		0.4 %	0.9 %	0.2 %	2.4 %	-0.2 %	1.6 %	3.0 %
6 months: -22.6	EV / Sales		6.9 x	7.5 x	3.6 x	2.9 x	3.5 x	3.0 x	2.6 x
Year to date: 28.5	% EV / EBITDA		41.7 x	43.1 x	28.6 x	20.5 x	36.6 x	21.8 x	15.6 x
Trailing 12 months: 70.9	% EV / EBIT		73.5 x	69.8 x	66.8 x	79.0 x	99.7 x	39.6 x	24.7 x
······································	P/E		92.0 x	105.3 x	79.9 x	47.9 x	139.9 x	51.6 x	32.4 x
Company events:	P / E adj.		92.0 x	105.3 x	79.9 x	47.9 x	139.9 x	51.6 x	32.4 x
	FCF Potential Yield		2.2 %	1.9 %	3.3 %	5.7 %	2.5 %	4.1 %	5.5 %
	Net Debt		156.89	149.11	158.30	87.41	90.70	67.38	23.11
	ROCE (NOPAT)		9.3 %	8.4 %	5.1 %	5.3 %	2.8 %	6.9 %	10.6 %
	Guidance:	2024: Revenu	e of at least l	EUR 400m; E	BIT betwee	n EUR 10m a	ind 20m		






Company Background

- The company, founded in 1999, is specialised as a property financing intermediary and is expanding its value chain towards the insurance and real estate sectors
- With EUROPACE, Hypoport operates the largest German online B2B platform for property financing and similar products
- Under the Dr. Klein brand, Hypoport operates a franchise system of stationary advisors for private customers
- Hypoport is also in a leading position in the area of institutional property financing (also under the Dr. Klein brand)
- An advanced level of technology is shown in all segments (fintech)

Competitive Quality

- The online B2B marketplace for property financing (EUROPACE) is the largest of its kind in Germany
- As the number of affiliated suppliers is decisive for marketplaces of this type, this forms a central competitive advantage and a considerable market entry barrier for third parties.
- The Dr. Klein business segments (private clients) benefits from market access over EUROPACE but also from the many years of experience in the area of property financing
- Most importantly however Dr. Klein is strongly focused on property financing and neutral (with offers from every provider). Other financial
 sales teams or retail banks normally cannot afford both.
- The new platform businesses insurance platform and real estate platform should strongly benefit of the market-leading credit platform and the excellent track record of the company.





DCF model														
	Detaile	d forecas	t period				٦	Fransitior	al period	ł				Term. Value
Figures in EUR m	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	
Sales	456.13	523.97	580.04	638.04	701.84	768.52	833.84	900.55	963.59	1,021.40	1,072.47	1,115.37	1,137.68	
Sales change	26.7 %	14.9 %	10.7 %	10.0 %	10.0 %	9.5 %	8.5 %	8.0 %	7.0 %	6.0 %	5.0 %	4.0 %	2.0 %	1.5 %
EBIT	15.82	39.24	61.21	76.56	105.28	138.33	175.11	216.13	250.53	285.99	300.29	312.30	318.55	
EBIT-margin	3.5 %	7.5 %	10.6 %	12.0 %	15.0 %	18.0 %	21.0 %	24.0 %	26.0 %	28.0 %	28.0 %	28.0 %	28.0 %	
Tax rate (EBT)	22.2 %	22.2 %	22.2 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	
NOPAT	12.31	30.53	47.62	59.72	82.12	107.90	136.58	168.58	195.42	223.07	234.23	243.60	248.47	
Depreciation	27.26	32.14	35.30	35.09	35.09	34.58	33.35	36.02	38.54	40.86	42.90	44.61	45.51	
in % of Sales	6.0 %	6.1 %	6.1 %	5.5 %	5.0 %	4.5 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	
Changes in provisions	0.00	0.00	0.00	0.14	0.06	0.07	0.07	0.07	0.06	0.06	0.05	0.04	0.02	
Change in Liquidity from														
- Working Capital	8.21	4.70	4.00	6.15	4.79	5.00	4.90	5.00	4.73	4.34	3.83	3.22	1.67	
- Capex	32.94	32.94	32.94	38.28	42.11	38.43	33.35	36.02	38.54	40.86	42.90	44.61	45.51	
Capex in % of Sales	7.2 %	6.3 %	5.7 %	6.0 %	6.0 %	5.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	
- Other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Free Cash Flow (WACC Model)	-1.58	25.03	45.99	50.52	70.38	99.12	131.75	163.65	190.75	218.80	230.45	240.42	246.82	251
PV of FCF	-1.56	22.65	38.18	38.49	49.21	63.61	77.60	88.45	94.62	99.60	96.28	92.18	86.85	1,183
share of PVs		2.92 %						38.7	3 %					58.30 %
Model parameter							Valuat	ion (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 2	036e	8	46			
							Termin	al Value		1,1	83			
Debt ratio	4.00 %		Financial S	Strength		1.10	Financ	ial liabilitie	s	1	84			
Cost of debt (after tax)	2.3 %		Liquidity (s	hare)		1.20	Pensio	n liabilities	i		0			
Market return	8.25 %		Cyclicality			1.30	Hybrid	capital			0			
Risk free rate	2.75 %		Transpare	псу		1.10	Minorit	y interest			2			
			Others			1.20	Market	val. of inv	estments		0			

Sensitivity Value per Share (EUR)

8.96 %

Beta

WACC

		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.37	10.0 %	232.82	236.40	240.18	244.19	248.44	252.96	257.77	1.37	10.0 %	226.61	232.47	238.33	244.19	250.05	255.91	261.77
1.27	9.5 %	252.16	256.40	260.89	265.67	270.75	276.18	281.98	1.27	9.5 %	246.89	253.15	259.41	265.67	271.93	278.19	284.45
1.23	9.2 %	262.76	267.38	272.29	277.52	283.10	289.06	295.46	1.23	9.2 %	258.08	264.56	271.04	277.52	284.00	290.48	296.97
1.18	9.0 %	274.05	279.10	284.48	290.22	296.35	302.92	309.99	1.18	9.0 %	270.06	276.78	283.50	290.22	296.93	303.65	310.37
1.13	8.7 %	286.11	291.63	297.53	303.84	310.60	317.87	325.69	1.13	8.7 %	282.93	289.90	296.87	303.84	310.81	317.78	324.75
1.09	8.5 %	298.99	305.06	311.55	318.50	325.97	334.02	342.71	1.09	8.5 %	296.77	304.01	311.26	318.50	325.74	332.98	340.22
0.99	8.0 %	327.62	334.98	342.88	351.39	360.59	370.56	381.40	0.99	8.0 %	327.84	335.69	343.54	351.39	359.24	367.09	374.94

1.18

Liquidity

Equity Value

97

1,940

No. of shares (m)

Value per share (EUR) 290.22

6.7

• The growth anticipated for Hypoport is based on robust business development in all segments

• Credit platform segment (EUROPACE) in particular offers systematic potential for economies of scale and margin growth

• On this basis we assume a positive long-term margin trend

- Based on a sophisticated regional dispersion of tax obligations a low tax rate is assumed long term.



Valuation							
	2020	2021	2022	2023	2024e	2025e	2026e
Price / Book	11.4 x	12.6 x	5.5 x	2.8 x	4.3 x	3.9 x	3.5 x
Book value per share ex intangibles	-13.76	-11.38	-12.06	-1.87	-1.78	1.44	7.47
EV / Sales	6.9 x	7.5 x	3.6 x	2.9 x	3.5 x	3.0 x	2.6 x
EV / EBITDA	41.7 x	43.1 x	28.6 x	20.5 x	36.6 x	21.8 x	15.6 x
EV / EBIT	73.5 x	69.8 x	66.8 x	79.0 x	99.7 x	39.6 x	24.7 x
EV / EBIT adj.*	73.5 x	69.8 x	66.8 x	79.0 x	99.7 x	39.6 x	24.7 x
P / FCF	252.7 x	116.8 x	577.0 x	40.9 x	n.a.	63.7 x	33.6 x
P/E	92.0 x	105.3 x	79.9 x	47.9 x	139.9 x	51.6 x	32.4 x
P / E adj.*	92.0 x	105.3 x	79.9 x	47.9 x	139.9 x	51.6 x	32.4 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	2.2 %	1.9 %	3.3 %	5.7 %	2.5 %	4.1 %	5.5 %
*Adjustments made for: -							

Consolidated profit & loss



In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Sales	387.73	446.35	455.45	359.89	456.13	523.97	580.04
Change Sales yoy	15.0 %	15.1 %	2.0 %	-21.0 %	26.7 %	14.9 %	10.7 %
Increase / decrease in inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Own work capitalised	20.78	23.62	23.99	23.16	24.63	28.29	31.32
Total Sales	408.51	469.97	479.44	383.05	480.77	552.26	611.36
Material expenses	177.20	196.86	194.47	151.72	218.18	240.20	257.16
Gross profit	231.31	273.10	284.97	231.33	262.58	312.06	354.19
Gross profit margin	59.7 %	61.2 %	62.6 %	64.3 %	57.6 %	59.6 %	61.1 %
Personnel expenses	133.88	155.46	176.45	159.57	171.90	189.25	202.61
Other operating income	6.61	5.64	8.99	28.10	5.29	6.79	7.27
Other operating expenses	40.48	46.06	59.46	48.68	52.89	58.23	62.34
Unfrequent items	0.28	-0.12	-0.34	0.00	0.00	0.00	0.00
EBITDA	63.85	77.10	57.71	51.18	43.08	71.38	96.51
Margin	16.5 %	17.3 %	12.7 %	14.2 %	9.4 %	13.6 %	16.6 %
Depreciation of fixed assets	14.70	13.49	13.46	12.88	12.27	14.46	15.88
EBITA	49.15	63.61	44.26	38.30	30.81	56.92	80.63
Amortisation of intangible assets	12.92	15.93	19.58	25.01	14.99	17.68	19.41
Goodwill amortisation	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT	36.24	47.68	24.68	13.30	15.82	39.24	61.21
Margin	9.3 %	10.7 %	5.4 %	3.7 %	3.5 %	7.5 %	10.6 %
EBIT adj.	36.24	47.68	24.68	13.30	15.82	39.24	61.21
Interest income	0.23	0.16	0.22	1.76	0.80	0.80	0.80
Interest expenses	3.07	3.59	3.28	3.03	3.00	3.00	3.00
Other financial income (loss)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBT	33.40	44.25	21.61	12.03	13.62	37.04	59.01
Margin	8.6 %	9.9 %	4.7 %	3.3 %	3.0 %	7.1 %	10.2 %
Total taxes	5.54	13.68	2.94	-8.46	3.02	8.22	13.10
Net income from continuing operations	27.86	30.58	18.67	20.49	10.60	28.82	45.91
Income from discontinued operations (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income before minorities	27.86	30.58	18.67	20.49	10.60	28.82	45.91
Minority interest	0.59	0.41	-0.02	0.36	0.00	0.00	0.00
Net income	27.27	30.16	18.69	20.14	10.60	28.82	45.91
Margin	7.0 %	6.8 %	4.1 %	5.6 %	2.3 %	5.5 %	7.9 %
Number of shares, average	6.25	6.25	6.30	6.68	6.68	6.68	6.68
EPS	4.36	4.83	2.96	3.01	1.59	4.31	6.87
EPS adj.	4.36	4.83	2.96	3.01	1.59	4.31	6.87
*Adjustments made for:							


Guidance: 2024: Revenue of at least EUR 400m; EBIT between EUR 10m and 20m

Financial Ratios


	2020	2021	2022	2023	2024e	2025e	2026e
Total Operating Costs / Sales	89.0 %	88.0 %	92.5 %	92.2 %	96.0 %	91.8 %	88.8 %
Operating Leverage	0.7 x	2.1 x	-23.6 x	2.2 x	0.7 x	10.0 x	5.2 x
EBITDA / Interest expenses	20.8 x	21.5 x	17.6 x	16.9 x	14.4 x	23.8 x	32.2 x
Tax rate (EBT)	16.6 %	30.9 %	13.6 %	-70.3 %	22.2 %	22.2 %	22.2 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Sales, EBITDA in EUR m


Source: Warburg Research



Operating Performance in %



Performance per Share




Source: Warburg Research



Consolidated balance sheet							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Assets							
Goodwill and other intangible assets	306.42	322.89	347.13	351.09	361.10	368.43	374.01
thereof other intangible assets	24.06	27.74	41.51	25.31	35.32	42.65	48.23
thereof Goodwill	221.96	222.41	222.41	229.08	229.08	229.08	229.08
Property, plant and equipment	97.66	101.89	95.58	67.27	62.94	56.42	48.47
Financial assets	0.40	0.78	0.96	1.21	1.21	1.21	1.21
Other long-term assets	28.96	28.30	21.41	27.68	27.68	27.68	27.68
Fixed assets	433.44	453.86	465.08	447.26	452.93	453.73	451.37
Inventories	1.51	1.50	1.07	0.94	1.00	1.00	1.00
Accounts receivable	75.20	83.03	75.12	68.54	75.00	86.10	95.30
Liquid assets	33.51	48.92	29.95	96.66	81.37	92.69	124.96
Other short-term assets	8.39	8.45	12.40	12.38	12.38	12.38	12.38
Current assets	118.61	141.91	118.53	178.52	169.75	192.17	233.64
Total Assets	552.00	595.80	583.60	625.80	622.70	645.90	685.00
Liabilities and shareholders' equity							
Subscribed capital	6.49	6.49	6.49	6.87	6.87	6.87	6.87
Capital reserve	65.77	66.93	67.56	114.54	114.54	114.54	114.54
Retained earnings	148.38	178.56	197.24	217.38	227.98	256.80	302.71
Other equity components	-0.19	-0.19	-0.19	-0.18	-0.18	-0.18	-0.18
Shareholders' equity	220.46	251.78	271.11	338.60	349.20	378.02	423.93
Minority interest	0.94	1.65	1.63	2.04	2.04	2.04	2.04
Total equity	221.39	253.43	272.74	340.64	351.24	380.06	425.97
Provisions	0.74	0.62	0.58	0.50	0.50	0.50	0.50
thereof provisions for pensions and similar obligations	0.74	0.62	0.58	0.50	0.50	0.50	0.50
Financial liabilities (total)	189.66	197.41	187.66	183.57	171.57	159.57	147.57
Short-term financial liabilities	14.02	16.11	16.92	20.75	20.75	20.75	20.75
Accounts payable	46.94	49.66	42.91	44.69	43.00	49.40	54.60
Other liabilities	93.31	94.65	79.73	56.37	56.37	56.37	56.37
Liabilities	330.66	342.34	310.88	285.13	271.44	265.84	259.04
Total liabilities and shareholders' equity	552.00	595.80	583.60	625.80	622.70	645.90	685.00

Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	3.0 x	3.3 x	3.5 x	3.9 x	4.8 x	5.6 x	6.4 x
Capital Employed Turnover	1.0 x	1.1 x	1.1 x	0.8 x	1.0 x	1.2 x	1.3 x
ROA	6.3 %	6.6 %	4.0 %	4.5 %	2.3 %	6.4 %	10.2 %
Return on Capital							
ROCE (NOPAT)	9.3 %	8.4 %	5.1 %	5.3 %	2.8 %	6.9 %	10.6 %
ROE	13.7 %	12.8 %	7.1 %	6.6 %	3.1 %	7.9 %	11.5 %
Adj. ROE	13.7 %	12.8 %	7.1 %	6.6 %	3.1 %	7.9 %	11.5 %
Balance sheet quality							
Net Debt	156.89	149.11	158.30	87.41	90.70	67.38	23.11
Net Financial Debt	156.15	148.49	157.72	86.91	90.21	66.89	22.61
Net Gearing	70.9 %	58.8 %	58.0 %	25.7 %	25.8 %	17.7 %	5.4 %
Net Fin. Debt / EBITDA	244.6 %	192.6 %	273.3 %	169.8 %	209.4 %	93.7 %	23.4 %
Book Value / Share	35.3	40.3	43.0	50.7	52.2	56.6	63.4
Book value per share ex intangibles	-13.8	-11.4	-12.1	-1.9	-1.8	1.4	7.5



COMMENT

Published 12.11.2024

Consolidated cash flow statement




In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net income	27.86	30.58	18.67	20.49	10.60	28.82	45.91
Depreciation of fixed assets	14.70	13.49	13.46	12.88	12.27	14.46	15.88
Amortisation of goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Amortisation of intangible assets	12.92	15.93	19.58	25.01	14.99	17.68	19.41
Increase/decrease in long-term provisions	-0.18	-0.12	-0.04	-0.08	0.00	0.00	0.00
Other non-cash income and expenses	-3.25	4.70	-9.83	-12.40	0.00	0.00	0.00
Cash Flow before NWC change	52.04	64.57	41.84	45.90	37.86	60.96	81.21
Increase / decrease in inventory	-0.42	0.01	0.05	0.13	-0.06	0.00	0.00
Increase / decrease in accounts receivable	-12.13	-7.83	11.31	6.58	-6.46	-11.10	-9.20
Increase / decrease in accounts payable	7.36	2.72	-14.64	1.78	-1.69	6.40	5.20
Increase / decrease in other working capital positions	-0.30	4.88	0.00	-0.90	0.00	0.00	0.00
Increase / decrease in working capital (total)	-5.49	-0.22	-3.28	7.59	-8.21	-4.70	-4.00
Net cash provided by operating activities [1]	46.55	64.35	38.56	53.49	29.64	56.26	77.21
Investments in intangible assets	-27.10	-30.02	-33.36	-22.25	-25.00	-25.00	-25.00
Investments in property, plant and equipment	-77.36	-17.81	-7.94	-7.94	-7.94	-7.94	-7.94
Payments for acquisitions	-22.90	-7.17	-7.91	-1.17	0.00	0.00	0.00
Financial investments	0.02	0.92	0.23	0.00	0.00	0.00	0.00
Income from asset disposals	0.05	0.53	1.64	-0.08	0.00	0.00	0.00
Net cash provided by investing activities [2]	-59.51	-44.71	-42.48	-31.17	-32.94	-32.94	-32.94
Change in financial liabilities	7.04	-4.23	-15.06	12.00	-12.00	-12.00	-12.00
Dividends paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of own shares	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital measures	14.54	0.00	0.00	50.00	0.00	0.00	0.00
Other	0.00	0.00	0.00	-0.93	0.00	0.00	0.00
Net cash provided by financing activities [3]	21.57	-4.23	-15.06	61.07	-12.00	-12.00	-12.00
Change in liquid funds [1]+[2]+[3]	8.62	15.41	-18.98	83.39	-15.29	11.32	32.27
Effects of exchange-rate changes on cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash and cash equivalent at end of period	33.51	48.92	29.95	113.33	81.37	92.69	124.96

Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
	2020	2021	2022	2023	20240	20256	20266
Cash Flow							
FCF	9.92	27.20	2.58	23.56	-3.29	23.32	44.27
Free Cash Flow / Sales	2.6 %	6.1 %	0.6 %	6.5 %	-0.7 %	4.5 %	7.6 %
Free Cash Flow Potential	58.31	63.42	54.77	59.65	40.06	63.16	83.41
Free Cash Flow / Net Profit	36.4 %	90.2 %	13.8 %	117.0 %	-31.1 %	80.9 %	96.4 %
Interest Received / Avg. Cash	0.8 %	0.4 %	0.6 %	2.8 %	0.9 %	0.9 %	0.7 %
Interest Paid / Avg. Debt	2.0 %	1.9 %	1.7 %	1.6 %	1.7 %	1.8 %	2.0 %
Management of Funds							
Investment ratio	26.9 %	10.7 %	9.1 %	8.4 %	7.2 %	6.3 %	5.7 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	378.4 %	162.5 %	125.0 %	79.7 %	120.8 %	102.5 %	93.3 %
Avg. Working Capital / Sales	7.0 %	7.2 %	7.5 %	8.1 %	6.3 %	6.7 %	6.8 %
Trade Debtors / Trade Creditors	160.2 %	167.2 %	175.1 %	153.4 %	174.4 %	174.3 %	174.5 %
Inventory Turnover	117.4 x	131.4 x	182.6 x	162.3 x	218.2 x	240.2 x	257.2 x
Receivables collection period (days)	71	68	60	70	60	60	60
Payables payment period (days)	97	92	81	108	72	75	77
Cash conversion cycle (Days)	-23	-21	-18	-36	-10	-14	-16

CAPEX and Cash Flow in EUR m



Free Cash Flow Generation

Published 12.11.2024

7

Working Capital

8.0 %

7.0 %

6.0 %

5.0 %

4.0 %

3.0 %

2.0 %

1.0 %

0.0 %

2026e

2025e



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- -4 MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)	
HYPOPORT	5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005493365.htm	



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	139	69
Hold	46	23
Sell	10	5
Rating suspended	6	3
Total	201	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	40	73
Hold	11	20
Sell	2	4
Rating suspended	2	4
Total	55	100

PRICE AND RATING HISTORY HYPOPORT AS OF 12.11.2024



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Hannes Müller Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Stefan Augustin Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com	Robert-Jan van der Horst Technology	+49 40 309537-290 rvanderhorst@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Marius Fuhrberg Financial Services Fabio Hölscher	+49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-240		
Automobiles, Car Suppliers Philipp Kaiser	+49 40 309537-240 fhoelscher@warburg-research.com +49 40 309537-260		
Real Estate, Construction Thilo Kleibauer	pkaiser@warburg-research.com +49 40 309537-257		
Retail, Consumer Goods	tkleibauer@warburg-research.com		
INSTITUTIONAL EQUI			
Klaus Schilling Head of Equity Sales, Germany	+49 69 5050-7400 kschilling@mmwarburg.com	Sascha Propp France	+49 40 3282-2656 spropp@mmwarburg.com
Tim Beckmann United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com		
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com		
Matthias Fritsch United Kingdom, Ireland	+49 40 3282-2696 mfritsch@mmwarburg.com	Leyan IIkbahar Roadshow/Marketing	+49 40 3282-2695 lilkbahar@mmwarburg.com
Rudolf Alexander Michaelis Germany	0	Antonia Möller Roadshow/Marketing	+49 69 5050-7417 amoeller@mmwarburg.com
Roman Alexander Niklas Switzerland, Poland, Italy	+49 69 5050-7412 rniklas@mmwarburg.com	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOR	RING
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading	omerckel@mmwarburg.com	Designated Sponsoring	mmagiera@mmwarburg.com
Rico Müller Sales Trading	+49 40 3282-2685 rmueller@mmwarburg.com	Sebastian Schulz Designated Sponsoring	+49 40 3282-2631 sschulz@mmwarburg.com
Bastian Quast	+49 40 3282-2701	Jörg Treptow	+49 40 3282-2658
Sales Trading	bquast@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be fe	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta	ct:		
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com